Most Golden Retrievers do not need an MDR1 test as a routine part of preventive care, because the mutation behind ivermectin sensitivity is not a breed-defining problem in this gundog line. The test becomes worth ordering when a dog has a known affected relative, when a breeder's records are incomplete, or when a veterinarian wants a documented genotype before using a high-dose macrocyclic lactone or a drug that depends on P-glycoprotein clearance. For everyone else, the decision is less about the breed and more about the individual dog's family history and the drugs that dog is likely to receive.
Does a Golden Retriever need an MDR1 test?
Owners who spend time around herding breeds learn to treat the ABCB1 mutation, formerly called MDR1, as a familiar risk. Collies, Australian Shepherds, Shetland Sheepdogs and several related lines carry it at a frequency that makes testing a standard step. A Golden Retriever owner usually comes to the question from the opposite direction: the breed is a retrieving gundog, not a herding breed, and the mutation is not part of the expected genetic picture. That expectation is reasonable, and it is the reason a blanket test for every Golden is not the default advice.
Expectation is not the same as certainty. A dog is an individual, and a Golden Retriever can inherit the mutation if one or both parents carry it, whatever the breed's overall profile suggests. The practical question is therefore not "does this breed carry MDR1" but "does this particular dog have a reason to be tested." Reasons include a parent or littermate with a known carrier or affected result, a pedigree that traces back to lines where the mutation has appeared, or a planned treatment that leaves little room for error. If none of those apply, an owner can reasonably file the question away and revisit it if circumstances change. Anyone weighing the wider day-to-day decisions of keeping this breed, from exercise to breeder selection, will find that context useful alongside the genetic one, and the same practical outlook applies to living with a Golden Retriever in Australia.
How is the MDR1 test done and how is the result read?
The test itself is simple and does not require a blood draw in most cases. A veterinarian or an owner collects a cheek swab, sometimes two, by rolling a small brush or swab inside the cheek for several seconds to pick up loose cells. The sample is dried, labeled and mailed to a laboratory that offers ABCB1 genotyping. Results typically return within a few weeks. Some laboratories also accept blood collected in an EDTA tube, and a few accept dewclaw or tissue samples, but the cheek swab is the usual route for a living pet.
The result comes back in one of three forms, and each has a distinct meaning.
Clear, sometimes written as normal or wild type, means the dog has two copies of the working gene. The dog is not expected to develop ivermectin toxicity from the ABCB1 defect and cannot pass the mutation to puppies.
Carrier means the dog has one copy of the mutation and one working copy. Carriers generally tolerate normal doses of the drugs in question, though some may be more sensitive than a clear dog, and they can pass the mutation to offspring. A carrier result matters most for breeding decisions.
Affected, sometimes written as homozygous mutant, means the dog has two copies of the mutation. These dogs have a defective P-glycoprotein pump at the blood-brain barrier, which normally keeps certain drugs out of the central nervous system. Affected dogs are at real risk of neurotoxicity from ivermectin at doses that are safe for other dogs, and from a small number of other drugs. The result is not a diagnosis of illness. It is a lifelong handling instruction.
What changes for parasite prevention once the result is known?
For a clear dog, nothing changes. Heartworm prevention at label dose, including the common monthly oral products, remains appropriate, and the owner can treat the test result as a closed question.
For a carrier, most veterinarians continue standard heartworm prevention at label dose, because the risk is tied to high-dose or off-label use rather than the small amounts in monthly preventives. The result mainly informs breeding and prompts a note in the record.
For an affected dog, the conversation shifts. Ivermectin at the doses used to treat mange, or at the higher end of some off-label protocols, is avoided. Monthly heartworm preventives that contain ivermectin or related macrocyclic lactones are usually still considered at label dose, because that dose is low and the label margin is wide, but the decision belongs to the veterinarian who knows the dog. Alternatives such as milbemycin or moxidectin are not automatically safer, since they act on the same pathway, and some affected dogs react to them as well. The practical rule is that any drug labeled as a P-glycoprotein substrate, including several anti-parasitics, some anti-nausea drugs and certain chemotherapy agents, is discussed before it is given rather than after.
What does the result change in the anaesthetic conversation?
An affected result changes the pre-anaesthetic checklist, not the decision to anaesthetise. Several drugs used in sedation and anaesthesia interact with P-glycoprotein, and the anaesthetist can plan around them. The owner's job is to make the result impossible to miss: it should be stated at the time the procedure is booked, written on the consent form, and repeated to the nurse who admits the dog. A dog with a clear result needs no special anaesthetic protocol on this basis alone.
Where does the answer belong in the dog's health record?
File the laboratory report with the rest of the dog's permanent health documents, alongside vaccination history, heartworm test results and any breed screening certificates. Keep a copy in the folder the owner brings to every veterinary visit and a digital copy in the same place as the microchip number. If the dog is bred, the result should also go to the breeder and to the owners of any puppies, because a carrier or affected parent changes what those buyers need to know. A result that lives only in an email inbox is a result that will be forgotten at the worst moment.
For a Golden Retriever owner, the honest summary is that MDR1 testing is a targeted tool, not a routine one. Order it when there is a family reason or a drug reason. Read the result as a handling instruction rather than a verdict. Then file it where the next veterinarian will find it.
The figures and testing rules cited above come from the WSU MDR1 programme, which sets out how the MDR1 test is performed, how a result is read, and what a positive or carrier result means for parasite prevention and for the anaesthetic conversation. Owners who want the primary source, rather than a summary, can read it directly. The same programme explains where the result belongs in the dog's health record, so a Golden Retriever's status travels with the dog to every clinic that treats it.